132 related articles for article (PubMed ID: 35504658)
21. Characterization of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of Velsecorat Using an Intravenous Microtracer Combined with an Inhaled Dose in Healthy Subjects.
Holmberg AA; Weidolf L; Necander S; Bold P; Sidhu S; Pelay-Gimeno M; de Ligt RAF; Verheij ER; Jauhiainen A; Psallidas I; Wählby Hamrén U; Prothon S
Drug Metab Dispos; 2022 Feb; 50(2):150-157. PubMed ID: 34853068
[TBL] [Abstract][Full Text] [Related]
22. The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma.
Foster JH; Barbieri E; Zhang L; Scorsone KA; Moreno-Smith M; Zage P; Horton TM
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207315
[TBL] [Abstract][Full Text] [Related]
23. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans.
Schwab D; Portron A; Backholer Z; Lausecker B; Kawashima K
Clin Pharmacokinet; 2013 Jun; 52(6):463-73. PubMed ID: 23494983
[TBL] [Abstract][Full Text] [Related]
24. Metabolic disposition of [
Wang L; Guo L; Wang Y; Guo R; Xu Z; Gao Z; Xie L; Chen J; Chen Y; Liu Y; Zhang H; Bao L; Xu W; Zhu M; Shao F; Shu Y
Br J Clin Pharmacol; 2021 Mar; 87(3):1475-1485. PubMed ID: 32959915
[TBL] [Abstract][Full Text] [Related]
25. Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.
Zhou X; Friedlander S; Kupperman E; Sedarati F; Kuroda S; Hua Z; Yuan Y; Yamamoto Y; Faller DV; Haikawa K; Nakai K; Bowen S; Dai Y; Venkatakrishnan K
Clin Transl Sci; 2021 May; 14(3):1069-1081. PubMed ID: 33503305
[TBL] [Abstract][Full Text] [Related]
26. Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Torka P; Kambhampati S; Chen L; Wang X; Chen C; Vuong D; Qin H; Muir A; Orand K; Borja I; Lynne Smith D; Herrera AF; Spurgeon SEF; Park B; Lewis LD; Hernandez-Ilizaliturri F; Xia Z; Danilov AV
Blood Cancer J; 2023 Jan; 13(1):9. PubMed ID: 36631449
[TBL] [Abstract][Full Text] [Related]
27. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.
Beconi MG; Reed JR; Teffera Y; Xia YQ; Kochansky CJ; Liu DQ; Xu S; Elmore CS; Ciccotto S; Hora DF; Stearns RA; Vincent SH
Drug Metab Dispos; 2007 Apr; 35(4):525-32. PubMed ID: 17220241
[TBL] [Abstract][Full Text] [Related]
28. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
Vincent SH; Reed JR; Bergman AJ; Elmore CS; Zhu B; Xu S; Ebel D; Larson P; Zeng W; Chen L; Dilzer S; Lasseter K; Gottesdiener K; Wagner JA; Herman GA
Drug Metab Dispos; 2007 Apr; 35(4):533-8. PubMed ID: 17220239
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure.
Zamek-Gliszczynski MJ; Abraham TL; Alberts JJ; Kulanthaivel P; Jackson KA; Chow KH; McCann DJ; Hu H; Anderson S; Furr NA; Barbuch RJ; Cassidy KC
Drug Metab Dispos; 2013 Apr; 41(4):714-26. PubMed ID: 23305709
[TBL] [Abstract][Full Text] [Related]
30. Cross-species comparison of the metabolism and excretion of zoniporide: contribution of aldehyde oxidase to interspecies differences.
Dalvie D; Zhang C; Chen W; Smolarek T; Obach RS; Loi CM
Drug Metab Dispos; 2010 Apr; 38(4):641-54. PubMed ID: 20040581
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice.
Pai CS; Khuat LT; Chen M; Murphy WJ; Abedi M
Biol Blood Marrow Transplant; 2017 Jan; 23(1):30-37. PubMed ID: 27815049
[TBL] [Abstract][Full Text] [Related]
32. The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2α and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia.
Leclerc GM; Zheng S; Leclerc GJ; DeSalvo J; Swords RT; Barredo JC
Leuk Res; 2016 Nov; 50():1-10. PubMed ID: 27626202
[TBL] [Abstract][Full Text] [Related]
33. An inhibitor of apoptosis protein antagonist T-3256336 potentiates the antitumor efficacy of the Nedd8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924).
Sumi H; Inazuka M; Morimoto M; Hibino R; Hashimoto K; Ishikawa T; Kuida K; Smith PG; Yoshida S; Yabuki M
Biochem Biophys Res Commun; 2016 Nov; 480(3):380-386. PubMed ID: 27771247
[TBL] [Abstract][Full Text] [Related]
34. Biotransformation of [
Pusalkar S; Plesescu M; Gupta N; Hanley M; Venkatakrishnan K; Wu JT; Xia C; Zhang X; Chowdhury S
Cancer Chemother Pharmacol; 2018 Nov; 82(5):803-814. PubMed ID: 30128949
[TBL] [Abstract][Full Text] [Related]
35. Absorption, Distribution, Metabolism, and Excretion of [
James AD; Kulmatycki K; Poller B; Romeo AA; Van Lier JJ; Klein K; Pearson D
Drug Metab Dispos; 2023 Jul; 51(7):873-883. PubMed ID: 37308298
[TBL] [Abstract][Full Text] [Related]
36. Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist:
Huynh C; Seeland S; Segrestaa J; Gnerre C; Hogeback J; Meyer Zu Schwabedissen HE; Dingemanse J; Sidharta PN
Front Pharmacol; 2022; 13():812065. PubMed ID: 35431953
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics, Disposition, and Biotransformation of [
Trivedi A; Wahlstrom J; Mackowski M; Dutta S; Lee E
Drug Metab Dispos; 2021 Aug; 49(8):619-628. PubMed ID: 34011533
[TBL] [Abstract][Full Text] [Related]
38. Sinusoidal Uptake Determines the Hepatic Clearance of Pevonedistat (TAK-924) as Explained by Extended Clearance Model.
Sandoval P; Chuang BC; Cohen L; Yoneyama T; Pusalkar S; Yucha RW; Chowdhury SK; Chothe PP
Drug Metab Dispos; 2022 Jul; 50(7):980-988. PubMed ID: 35545257
[TBL] [Abstract][Full Text] [Related]
39. Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs.
Hong H; Su H; Sun H; Allentoff A; Ekhato IV; Chando T; Caceres-Cortes J; Roongta V; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2010 Jul; 38(7):1189-201. PubMed ID: 20363952
[TBL] [Abstract][Full Text] [Related]
40. Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human.
Sharma R; Sun H; Piotrowski DW; Ryder TF; Doran SD; Dai H; Prakash C
Drug Metab Dispos; 2012 Nov; 40(11):2143-61. PubMed ID: 22896728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
